Search Result

Results for "

PPARα+agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) ATP Citrate Lyase (1) Autophagy (9) Bacterial (4) Cannabinoid Receptor (1) Cytochrome P450 (6) Drug Intermediate (1) Endogenous Metabolite (4) Fungal (1) Influenza Virus (1) Isotope-Labeled Compounds (7) Keap1-Nrf2 (1) NF-κB (1) NOD-like Receptor (NLR) (1) Phosphatase (1) PPAR (55) Pyroptosis (1) Reactive Oxygen Species (ROS) (3) Reference Standards (7) Sirtuin (1) SOD (3) Stearoyl-CoA Desaturase (SCD) (1) STING (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (24) Infection (5) Inflammation/Immunology (17) Metabolic Disease (29) Neurological Disease (6)

By Targets:

Apoptosis (1)

ATP Citrate Lyase (1)

Autophagy (9)

Bacterial (4)

Cannabinoid Receptor (1)

Cytochrome P450 (6)

Drug Intermediate (1)

Endogenous Metabolite (4)

Fungal (1)

Influenza Virus (1)

Isotope-Labeled Compounds (7)

Keap1-Nrf2 (1)

NF-κB (1)

NOD-like Receptor (NLR) (1)

Phosphatase (1)

PPAR (55)

Pyroptosis (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (7)

Sirtuin (1)

SOD (3)

Stearoyl-CoA Desaturase (SCD) (1)

STING (1)

Toll-like Receptor (TLR) (1)

By Research Areas:

Cancer (9)

Cardiovascular Disease (24)

Infection (5)

Inflammation/Immunology (17)

Metabolic Disease (29)

Neurological Disease (6)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17356

Fenofibrate Maximum Cited Publications 33 Publications Verification	PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate is a selective *PPARα* agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-13861

GW7647 20+ Cited Publications	PPAR	Cardiovascular Disease
GW7647 is a potent *PPARα* agonist, with EC₅₀s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-17618

Pemafibrate 5+ Cited Publications (R)-K-13675	PPAR	Cardiovascular Disease Inflammation/Immunology
Pemafibrate is a highly selective *PPARα* agonist, with an EC₅₀ of 1 nM.

HY-107542

Oleoylethanolamide 3 Publications Verification N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide	Endogenous Metabolite PPAR	Cardiovascular Disease Metabolic Disease
Oleoylethanolamide is a high affinity endogenous *PPAR-α* agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-N0783

Eupatilin Maximum Cited Publications 8 Publications Verification	PPAR Autophagy	Neurological Disease Inflammation/Immunology Cancer
Eupatilin, a lipophilic flavonoid isolated from Artemisia argyi Lévl. et Van., is a PPARα* agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.*

HY-N1990

Gypenoside XLIX 2 Publications Verification	PPAR Sirtuin Keap1-Nrf2 Toll-like Receptor (TLR) NF-κB Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Apoptosis Pyroptosis Autophagy	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a K_a value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a *PPAR-α* agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation .

HY-W081067

Perfluoro(2-methyl-3-oxahexanoic) acid HFPO-DA	PPAR	Infection
Perfluoro (2-methyl-3-oxahexanoic) acid (HFPO-DA) is an orally active *PPARα* agonist with an EC₅₀ of 2.1 μM for human PPARα. Perfluoro (2-methyl-3-oxahexanoic) acid induces peroxisome proliferation and increases the levels of proinflammatory mediators. It impairs intestinal barrier function and disrupts cecal flora balance. Perfluoro (2-methyl-3-oxahexanoic) acid is applicable to research related to developmental toxicity, hepatotoxicity and intestinal toxicity .

HY-B1415

Clofibric acid Chlorofibrinic acid	PPAR Bacterial SOD	Infection Metabolic Disease Cancer
Clofibric acid (Chlorofibrinic acid) is an orally active *PPARα* agonist. Clofibric acid inhibits the fimbriation of *Escherichia coli. Clofibric acid increases SOD* activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research .

HY-10678

BMS-687453 3 Publications Verification	PPAR	Cardiovascular Disease
BMS-687453 is a potent and selective *PPARα* agonist, with an EC₅₀ and IC₅₀ of 10 nM and 260 nM for human PPARα and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.

HY-50665

LY518674 LY-674	PPAR	Metabolic Disease
LY518674 is a potent, selective *PPARα* agonist, with an EC₅₀ of 42 nM for human PPARα. LY518674 reduces triglycerides in and increased HDL-C and is used for the treatment of atherosclerosis .

HY-W128156

10-Hydroxystearic acid 10-HSA	PPAR	Inflammation/Immunology
10-Hydroxystearic acid (10-HSA) is a *PPARα* agonist. 10-Hydroxystearic acid stimulates collagen synthesis. 10-Hydroxystearic acid is an anti-aging agent and reduces the appearance of pores and hyperpigmented lesions .

HY-106278

GW 590735 1 Publications Verification	PPAR	Metabolic Disease
GW 590735 is a potent and selective *PPARα* agonist. GW 590735 showsEC₅₀=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .

HY-17356S

Fenofibrate-d6	Isotope-Labeled Compounds PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-107542S

Oleoylethanolamide-d4 N-Oleoylethanolamide-d₄; Oleamide MEA-d₄; Oleic acid monoethanolamide-d₄	Isotope-Labeled Compounds Endogenous Metabolite PPAR	Cardiovascular Disease Metabolic Disease
Oleoylethanolamide-d₄ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-107542S2

Oleoylethanolamide-d2 N-Oleoylethanolamide-d₂; Oleamide MEA-d₂; Oleic acid monoethanolamide-d₂	Isotope-Labeled Compounds Endogenous Metabolite PPAR	Cardiovascular Disease Metabolic Disease
Oleoylethanolamide-d₂ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-129683

AM3102	PPAR	Metabolic Disease
AM3102 is an oleoylethanolamide (OEA) analog. AM3102 is an endogenous high-affinity PPAR-alpha agonist. AM3102 resists enzymatic hydrolysis, activates PPAR-alpha with high potency in vitro, and persistently reduces feeding when administered in vivo either parenterally or orally .

HY-108571

CP-775146	PPAR	Cardiovascular Disease Metabolic Disease
CP-775146 is a selective *PPARα* agonist (K_i of 24.5 nM) that binds strongly to the PPARα ligand. CP-775146 has no observable affinity for PPARβ and PPARγ.CP-775146 shows hypolipidemic activity. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway .

HY-17356R

Fenofibrate (Standard) Maximum Cited Publications 33 Publications Verification	Reference Standards PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate (Standard) is the analytical standard of Fenofibrate. This product is intended for research and analytical applications. Fenofibrate is a selective *PPARα* agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-139177

PPARα agonist 2	PPAR	Cardiovascular Disease
PPARα agonist 2 (compound 4u) is a potent and selective *PPARα* agonist with an EC₅₀ of 37 nM. PPARα agonist 2 exhibits >2,700-fold selectivity for PPARα over other PPAR isoforms. PPARα agonist 2 has the potential for retinal disorders research .

HY-17618S

Pemafibrate-d4 (R)-K-13675-d₄	PPAR Isotope-Labeled Compounds	Inflammation/Immunology
Pemafibrate-d₄ is deuterated labeled Pemafibrate (HY-17618). Pemafibrate is a highly selective PPARα agonist, with an EC₅₀ of 1 nM.

HY-107542R

Oleoylethanolamide (Standard) N-Oleoylethanolamide (Standard); Oleamide MEA (Standard); Oleic acid monoethanolamide (Standard)	Reference Standards Endogenous Metabolite PPAR	Cardiovascular Disease Metabolic Disease
Oleoylethanolamide (Standard) is the analytical standard of Oleoylethanolamide. This product is intended for research and analytical applications. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-113820

AZD4619	PPAR	Metabolic Disease
AZD4619 is an orally active, selective peroxisome proliferator-activated receptor α (PPARα) agonist. AZD4619 increases alanine aminotransferase 1 (ALT1) protein expression in a dose-dependent manner in human, but not in rat primary hepatocytes. AZD4619 is a lipid-lowering drug .

HY-N9768

(10E,12E)-9-Oxo-10,12-octadecadienoic acid 9-oxo-ODA	Fungal PPAR	Infection
(10E,12E)-9-Oxo-10,12-octadecadienoic acid (9-oxo-ODA) is a *PPARα* agonist that can be isolated from the basidiomycete Gomphus floccosus. (10E,12E)-9-Oxo-10,12-octadecadienoic acid enhances fatty acid oxidation through PPARα activation, thereby inhibiting triglyceride accumulation. (10E,12E)-9-Oxo-10,12-octadecadienoic acid also has antifungal (Fungal) activity .

HY-176971

PPARα agonist 6	PPAR	Cardiovascular Disease Metabolic Disease
PPARα agonist 6 (Compound 15) is a *PPARα* agonist. PPARα agonist 6 can be used in the research of dyslipidemia .

HY-159146

PPARα agonist 4	PPAR STING Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology
PPARα agonist 4 (compound BH400) is a *PPARα* agonist (EC₅₀= 1.2 μM). PPARα agonist 4 also inhibits STING (IC₅₀: 8.1 μM). PPARα agonist 4 reduces the CoCl₂-induced production of ROS and LPS-induced secretion of IL-6. The PPARα agonist 4 restores the decreased expression of PCG1α induced by LPS .

HY-163862

PPARα agonist 3	PPAR Reactive Oxygen Species (ROS)	Inflammation/Immunology
PPARα agonist 3 (Compound A229) is a *PPARα* agonist (EC₅₀: 590 nM). PPARα agonist 3 inhibits TBHP or 4-HNE (HY-113466)-induced production of ROS .

HY-173217

PPARα agonist 5	PPAR Phosphatase	Cardiovascular Disease Metabolic Disease
PPARα agonist 5 is an orally available, selective partial agonist of PPARα (EC₅₀: 3 nM). PPARα agonist 5 reduces lipid accumulation and upregulates key PPARα target genes, exerting anti-fatty liver effects. PPARα agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC₅₀: 79.1 μM). PPARα agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia .

HY-146733

PPARα agonist 1	PPAR	Inflammation/Immunology
PPARα agonist 1 is a potent and full hPPARα agonist .

HY-U00014

AVE-8134	PPAR	Metabolic Disease
AVE-8134 is a potent *PPARα* agonist, with EC₅₀ values of 100 and 3000 nM for human and rodent PPARα receptor, respectively.

HY-N6807S

Elemicin-d3	Bacterial Influenza Virus Stearoyl-CoA Desaturase (SCD) Isotope-Labeled Compounds	Cancer
Elemicin-d₃ is deuterated labeled Pemafibrate (HY-17618). Pemafibrate is a highly selective *PPARα* agonist, with an EC₅₀ of 1 nM.

HY-156977

Sitofibrate	PPAR	Cardiovascular Disease
Sitofibrate is a Clofibrate (HY-B0287) derivative. Sitofibrate is aperoxisome proliferator activated receptor-α (PPAR-α) agonist. Sitofibrate is an antihyperlipidemic agent .

HY-117196

GW 9578 1 Publications Verification	PPAR	Metabolic Disease Inflammation/Immunology
GW9578 is a subtype-selective *PPARα* agonist (EC₅₀s of 5 and 50 nM for murine and human PPAR-α) with potent lipid-lowering activity .

HY-N0783R

Eupatilin (Standard)	Reference Standards PPAR Autophagy	Neurological Disease Inflammation/Immunology Cancer
Eupatilin (Standard) is the analytical standard of Eupatilin. This product is intended for research and analytical applications. Eupatilin, a lipophilic flavonoid isolated from Artemisia argyi Lévl. et Van., is a PPARα* agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.*

HY-107054

ESP-31015 ETC-1001	PPAR	Cardiovascular Disease
ESP-31015 (ETC-1001) is an orally active and non-fibrate based *PPARα* agonists. ESP-31015 demonstrates significant lipid-regulating effects in the obese Zucker rat model. ESP-31015 can be used in cardiovascular disease research .

HY-19425

NS-220	PPAR	Metabolic Disease
NS-220 is an orally active *PPARα* agonist with high subtype selectivity, with EC₅₀ values of 1.9×10 ^-8 M, 9.6×10 ^-6 M and >10 ^-4 M for PPARα, PPAR γ and PPARδ, respectively. NS-220 is used in the research for hyperlipidemia or metabolic disorders in type-2 diabetes .

HY-17356G

Fenofibrate	Cytochrome P450 PPAR Autophagy	Cardiovascular Disease
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective *PPARα* agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-17618R

Pemafibrate (Standard) (R)-K-13675 (Standard)	Reference Standards PPAR	Inflammation/Immunology
Pemafibrate (Standard) is the analytical standard of Pemafibrate. This product is intended for research and analytical applications. Pemafibrate is a highly selective *PPARα* agonist, with an EC₅₀ of 1 nM.

HY-117131

ZINC17167211	PPAR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
ZINC17167211 is a potent *PPAR-α* agonist (EC₅₀=0.16 nM) that can be used in the study of diabetes, hyperlipidemia, and inflammatory diseases .

HY-114700

ZINC08438472	PPAR	Metabolic Disease Inflammation/Immunology
ZINC08438472 is a potent and selective peroxisome proliferator activated receptors-α (PPAR-α) agonist with an EC₅₀ value of 12.1 nM. ZINC08438472 is promising for research of diabetes, hyperlipidaemia and inflammatory disorders .

HY-106027

Romazarit RO 31-3948	PPAR	Metabolic Disease Inflammation/Immunology
Romazarit (RO 31-3948) is an anti-inflammatory agent with antirheumatic effect. Romazarit exhibits *PPARα* agonist activity. Romazarit (30 mg/kg) inhibits the development of hindpaw inflammation in an adjuvant arthritis model .

HY-19418

KRP-101	PPAR	Others
KRP-101 is a compound that regulates the expression of genes related to lipid metabolism. It is a PPARα agonist that can highly sensitively regulate the expression of genes such as apolipoprotein A-IV, which may be related to lowering serum triglycerides and increasing HDL.

HY-13861R

GW7647 (Standard)	PPAR	Cardiovascular Disease
GW7647 (Standard) is the analytical standard of GW7647. This product is intended for research and analytical applications. GW7647 is a potent PPARα agonist, with EC50s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-116699

CP-868388 free base	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
CP-868388 free base is a potent, selective and orally active *PPARα* agonist with a K_i value of 10.8 nM. CP-868388 free base has little or no affinity for PPARβ (K_i of 3.47 μM) and PPARγ. CP-868388 free base has hypolipidemic and anti-inflammatory actions .

HY-120943

K-111 BM 17.0744	PPAR	Metabolic Disease
K-111 (BM-170744) is an oral active *PPAR alpha* agonist. K-111 show efficacy in improving insulin resistance, reducing body weight, and ameliorating atherogenic dyslipidemia. K-111 can be used for study of type 2 diabetes, dyslipidaemia, obesity and the metabolic syndrome .

HY-165393

Elaidyl-sulfamide N-(9E)-9-Octadecen-1-ylsulfamide	PPAR	Metabolic Disease
Elaidyl-sulfamide (N-(9E)-9-Octadecen-1-ylsulfamide) is a *PPARα* agonist. Elaidyl-sulfamide reduces body weight gain and food intake and reduces circulating cholesterol levels and increases both glucose and insulin levels. Elaidyl-sulfamide has the potential for the research of complicated obesity .

HY-139230

OLHHA	Cannabinoid Receptor PPAR	Metabolic Disease
OLHHA is a dual CB1 receptor antagonist and *PPARα* agonist. OLHHA also is a alcohol intake inhibitor with an EC₅₀ value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD) .

HY-128135

MHY 553	PPAR	Inflammation/Immunology
MHY 553 is a *PPARα* agonist that is effective when taken orally. MHY 553 helps alleviate liver fat accumulation by increasing fatty acid oxidation and reducing inflammation during the aging process. MHY 553 inhibits the accumulation of triglycerides induced by liver X receptor agonists in HepG2 cells. MHY 553 significantly suppresses the expression of inflammatory mRNA in aging rats .

HY-106278A

GW 590735 sodium	PPAR	Metabolic Disease
GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735 .

HY-17356S2

Fenofibrate-13C6	Isotope-Labeled Compounds Cytochrome P450 PPAR Autophagy	Cardiovascular Disease
Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective *PPARα* agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-17356S1

Fenofibrate-d4	PPAR Autophagy Cytochrome P450	Cardiovascular Disease
Fenofibrate-d₄ is the deuterium labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107542

Oleoylethanolamide 3 Publications Verification N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide	Cardiovascular Disease Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite PPAR
Oleoylethanolamide is a high affinity endogenous *PPAR-α* agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-N0783

Eupatilin Maximum Cited Publications 8 Publications Verification	Flavonoids Neurological Disease Classification of Application Fields Flavones Plants Compositae Disease Research Fields Sindora sumatrana Miq. Cancer	PPAR Autophagy
Eupatilin, a lipophilic flavonoid isolated from Artemisia argyi Lévl. et Van., is a PPARα* agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.*

HY-N1990

Gypenoside XLIX 2 Publications Verification	Cardiovascular Disease Triterpenes Structural Classification Classification of Application Fields Terpenoids Cucurbitaceae Plants Gynostemma pentaphyllum (Thunb.) Makino Disease Research Fields Source Classification	PPAR Sirtuin Keap1-Nrf2 Toll-like Receptor (TLR) NF-κB Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Apoptosis Pyroptosis Autophagy
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a K_a value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a *PPAR-α* agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation .

HY-107542R

Oleoylethanolamide (Standard) N-Oleoylethanolamide (Standard); Oleamide MEA (Standard); Oleic acid monoethanolamide (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite PPAR
Oleoylethanolamide (Standard) is the analytical standard of Oleoylethanolamide. This product is intended for research and analytical applications. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-N9768

(10E,12E)-9-Oxo-10,12-octadecadienoic acid 9-oxo-ODA	Microorganisms Ketones, Aldehydes, Acids Source Classification	Fungal PPAR
(10E,12E)-9-Oxo-10,12-octadecadienoic acid (9-oxo-ODA) is a *PPARα* agonist that can be isolated from the basidiomycete Gomphus floccosus. (10E,12E)-9-Oxo-10,12-octadecadienoic acid enhances fatty acid oxidation through PPARα activation, thereby inhibiting triglyceride accumulation. (10E,12E)-9-Oxo-10,12-octadecadienoic acid also has antifungal (Fungal) activity .

HY-N0783R

Eupatilin (Standard)	Flavonoids Neurological Disease Classification of Application Fields Plants Compositae Disease Research Fields Sindora sumatrana Miq. Source Classification Cancer	Reference Standards PPAR Autophagy
Eupatilin (Standard) is the analytical standard of Eupatilin. This product is intended for research and analytical applications. Eupatilin, a lipophilic flavonoid isolated from Artemisia argyi Lévl. et Van., is a PPARα* agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.*

Cat. No.	Product Name	Chemical Structure

HY-17356S

Fenofibrate-d6
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-107542S

Oleoylethanolamide-d4
Oleoylethanolamide-d₄ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-107542S2

Oleoylethanolamide-d2
Oleoylethanolamide-d₂ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-17618S

Pemafibrate-d4
Pemafibrate-d₄ is deuterated labeled Pemafibrate (HY-17618). Pemafibrate is a highly selective PPARα agonist, with an EC₅₀ of 1 nM.

HY-N6807S

Elemicin-d3
Elemicin-d₃ is deuterated labeled Pemafibrate (HY-17618). Pemafibrate is a highly selective *PPARα* agonist, with an EC₅₀ of 1 nM.

HY-17356S2

Fenofibrate-13C6
Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective *PPARα* agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-17356S1

Fenofibrate-d4
Fenofibrate-d₄ is the deuterium labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively .

HY-B1415S

Clofibric acid-d4

Clofibric acid-d₄ is the deuterium labeled Clofibric acid (HY-B1415). Clofibric acid also is an herbicideClofibric acid (Chlorofibrinic acid) is an orally active PPARα agonist. Clofibric acid inhibits the fimbriation of Escherichia coli. Clofibric acid increases SOD activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17356G

Fenofibrate	Cytochrome P450 PPAR Autophagy	Cardiovascular Disease
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective *PPARα* agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PPARα+agonist

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products